Is Vir Biotechnology (NASDAQ:VIR) In A Good Position To Deliver On Growth Plans? [Yahoo! Finance]
Vir Biotechnology, Inc. (VIR)
Company Research
Source: Yahoo! Finance
For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly. So should Vir Biotechnology NASDAQ:VIR ) shareholders be worried about its cash burn? In this report, we will consider the company's annual negative free cash flow, henceforth referring to it as the 'cash burn'. First, we'll determine its cash runway by comparing its cash burn with its cash reserves. Check out our latest analysis for Vir Biotechnology Does Vir Biotechnology Have A Long Cash Runway? A company's cash runway is the amount of time it would take to burn through its cash reserves at its current cash burn rate. In March 2024, Vir Biotechnology had US$1.1b in cash, and was debt-free. Looking at the last year, the company burnt through US$779m. That means it had a cash runway of around 18 months as of March 2024. Whi
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta Infection [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology Receives FDA IND Clearance and Fast Track Designation for Tobevibart and Elebsiran for the Treatment of Chronic Hepatitis Delta InfectionBusiness Wire
- Vir Biotechnology (VIR) Up on Positive Data From HDV Study [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at Morgan Stanley from $12.00 to $15.00. They now have an "equal weight" rating on the stock.MarketBeat
- Vir Biotechnology, Inc. (NASDAQ: VIR) had its price target raised by analysts at Needham & Company LLC from $15.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
VIR
Earnings
- 5/2/24 - Beat
VIR
Sec Filings
- 6/26/24 - Form 8-K
- 6/12/24 - Form 4
- 6/12/24 - Form 4
- VIR's page on the SEC website